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Investigating the effects of homocysteine as an agonist on invertebrate 
glutamatergic synapses 
Elizabeth Grau, Alexandra E. Stanback, Alec Bradley, Danielle Cantrell, Samantha 
Eversole, Carolyn Grachen, Kaylee Hall, Danielle Hawthorne, Claire Kinmon, Paula Ortiz 
Guerrero, Bhavik Patel, Kaitlyn Samuels, Chinni Suryadevara, Gia Valdes, Samuel Wycoff 
and Robin L. Cooper 
Department of Biology, University of Kentucky, Lexington, KY, USA 
 
Hyperhomocysteinemia (HHcy) in mammals can produce neurological deficits, such as memory 
loss. The cause of the neurological issues is assumed to be due to homocysteine (HCY) binding to 
glutamatergic receptors in the central nervous system (CNS). High levels of HCY in the CNS are 
also associated with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s disease. Thus, 
understanding the detailed mechanisms of HCY in model preparations could be useful in 
developing potential treatments to neurodegenerative diseases with overlapping symptoms to 
HHcy. The aim of this study is to investigate the efficacy of HCY as an agonist at glutamatergic 
synapses in invertebrates. The glutamatergic synapses of the larval Drosophila melanogaster (D. 
melanogaster) and Procambarus clarkii (P. clarkii) neuromuscular junctions (NMJs) were utilized 
to examine the effects of applying HCY. Measurements of evoked synaptic transmission in both 
preparations revealed that 100 mM of HCY did not have any consistent effect. The expectation 
was that the acute action of HCY would have activated the glutamate receptors and then 
desensitized them so evoked transmission would be blocked. The pharmacological receptor profile 
of these NMJ receptors are of a quisqualate subtype and not a kainate, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) or N-methyl-D-aspartate receptor (NMDA) subtype. 
Consequently, HCY may not have any action on quisqualate glutamate receptor subtypes. The 
findings of this experiments could provide clinical implications regarding relevant 
pharmacological treatments in neurodegenerative diseases such as amyotrophic lateral sclerosis 
(ALS) and Parkinson’s disease. 
 
 
Abbreviations:  ACURE— authentic course-based undergraduate research experience; AMPA— 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; EPSP— excitatory 
postsynaptic potential; HCY— homocysteine; HHcy— Hyperhomocysteinemia; NMDA— N-
methyl-D-aspartate receptor; NMJ— neuromuscular junction 
Keywords — ACh, glutamate, Homocysteine, Drosophila melanogaster, invertebrate, 
pharmacology, Procambarus clarkii, receptor   
_____________________________________________________________________________________ 
Introduction 
Homocysteine (HCY) is an amino acid 
intermediate produced in the central nervous 
system (CNS) in the metabolism of methionine to 
cysteine. The actions of HCY in mammals and 
the associated pathological state of high plasma 
HCY levels, known as hyperhomocysteinemia 
(HHcy), in part, revolve around the actions of 
HCY on glutamatergic receptors (Lipton et al., 
1997; Poddar and Paul, 2013; Abushik et al., 
2014; Bukharaeva et al., 2015). Glutamate is an 
excitatory neurotransmitter that acts at 
glutamatergic receptors, particularly N-methyl-
D-aspartic acid (NMDA) receptors. HCY is 
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produced in the CNS and can act as an excitatory 
transmitter activating both NMDA and non-
NMDA glutamate receptors in mammalian 
models. In this study we examined the potential 
action of HCY on the non-NMDA glutamate 
receptors. In particular, we tested the action of 
HCY on the quisqualate receptor subtype which 
is of a non-NMDA subtype Even at the 
acetylcholine (Ach) transmitting neuromuscular 
junctions (NMJs) of mammals, it has been 
established that there are NMDA receptor 
subunits which are affected by HCY (Bukharaeva 
et al., 2015).  
Glutamate receptors are defined as 
NMDA (N-methyl-D-aspartic acid) and non-
NMDA subtypes (i.e., AMPA, kainate, δ and 
quisqualate) based on their pharmacological 
sensitivity (Lee et al., 2009). The importance of 
the receptor subtypes is in understanding the 
action of the cells expressing them. NMDA 
receptors are ionotropic and allow an influx of 
Ca2+ ions when open, which can lead to a number 
of cellular responses and even cell death 
(Verdoorn et al., 1991). Kainate receptors in 
mammals are of a metabotropic subtype and work 
through second messenger cascades. They are 
even known to be present on presynaptic nerve 
terminals to reduce evoked transmitter release via 
autoreceptors on the presynaptic terminals (Park 
et al., 2006). NMDA and kainate subtypes 
produce a lower percentage of desensitization 
than the quisqualate receptor subtype (Thio et al., 
1991). The compounds kainate, NMDA and 
AMPA do not activate the glutamate ligand gated 
ion channels at the larval Drosophila 
melanogaster (D. melanogaster) NMJ but 
quisqualate does (Bhatt and Cooper, 2005; Dudel 
et al., 1992) (  
 
The action of HCY at the mammalian 
NMJs can be blocked by application of the 
glutamate competitive antagonist AP-5 
(Bukharaeva et al., 2015). Additionally, there is a 
strong correlation with HHcy in mammals with 
high plasma and cerebrospinal fluid levels of 
HCY to the motor neuronal disease, amyotrophic 
lateral sclerosis (ALS) (Bukharaeva et al., 2015; 
Veeranki and Tyagi, 2013). Over-activation of 
glutamatergic drive on motor neurons has been 
shown to facilitate the disease state of ALS 
through subsequent degradation of the motor 
neurons (Vucic and Kiernan, 2009). Riluzole, a 
glutamatergic antagonist within the central 
nervous system (CNS), works as an effective 
treatment in ALS patients through reduction of 
glutamatergic activation on motor neurons 
(Vucic and Kiernan, 2009; Miller et al., 2012; 
Doble, 1996). As highlighted by Yohay et al., 
(2014), Riluzole also doubles as an effective 
treatment in rodent models of CNS injury as well 
as neurodegenerative states such as Parkinson’s 
disease. Thus, HCY has the potential to maybe 
act similarly to Riluzole for potential treatments. 
HCY has also been shown to restore 
sensitization of glutamatergic receptors in rodent 
neurons, which may account for the larger ionic 
currents of the glutamate receptors (Bolton et al., 
2013). It has been demonstrated that an enzyme 
deficiency in rodents of 
methylenetetrahydrofolate reductase leads to an 
increase in neuronal damage by HCY and results 
in an increase in γ-aminobutyric acid (GABA) 
within the CNS which is assumed to compensate 
for the higher HCY levels (Jadavji et al., 2015). 
Also, HCY has an antagonistic action on GABA 
receptors (Tyagi et al., 2005). The actions on 
GABA receptors could, in part, account for the 
effect of HCY and the resulting pathologies in 
mammals exhibiting HHcy (Tyagi et al., 2005). 
GABA is an inhibitory receptor subtype, 
conducting actions via G-proteins to limit Ca2+ 
within the cell during synaptic transmission 
(Olsen and DeLorey, 1999). Antagonistic actions 
of HCY on GABA receptors could result in 
prevention of inhibition of glutamatergic receptor 
action. Therefore, the result of such an interaction 
could be the production a summative excitatory 
response that would contribute to neuronal death 
and subsequent blood brain barrier degradation 
experienced in the presence of excess HCY.  
How the precise mechanisms of action of 
HCY on various neurotransmitter receptors and 
synaptic transmission may be altered are still 
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being investigated. It is established that HCY can 
act on both NMDA and non-NMDA receptors in 
rodent models (Yuzaki and Connor, 1999). The 
glutamatergic NMJs of larval D. melanogaster 
and Procambarus clarkii (P. clarkii) are of a non-
NMDA subtype. Given that HCY is known to be 
synthesized in D. melanogaster (Caggese et al., 
1997), it is likely it is present in other arthropods 
such as the crayfish P. clarkii. The investigations 
to date are primarily focused on mammalian CNS 
models; however, some aspects of precise quantal 
measures of synaptic transmission are more 
challenging in mammalian models compared to 
those at invertebrate NMJs.  This difference is 
due to the ability to record at synaptic sites in 
invertebrate models. Furthermore, the potential 
effects of HCY on synaptic facilitation and 
synaptic depression have not been thoroughly 
investigated in mammalian models.  
However, such information could 
provide clinical implications regarding diseases 
that have been shown to exhibit relationships 
with HCY pathology, such as Parkinson’s disease 
and ALS. Thus, the purpose of this experiment is 
to gain insight into the mechanisms of action of 
HCY at the NMJs of model organisms. These 
experiments were designed to test the prediction 
that application of HCY to model systems would 
produce an initial overstimulation of 
glutamatergic receptors followed by quick 
desensitization.  
P. clarkii NMJs have served as a classic 
model in glutamatergic synaptic facilitation and 
depression (Richet, 1879; Katz, 1949; Sherman 
and Atwood, 1971; see recent reviews Cooper 
and Cooper, 2009; Titlow and Cooper, 2018). D. 
melanogaster NMJs have also been utilized for 
the same purpose due to their utility as a genetic 
model for mutational defects in synaptic 
transmission afflicting humans (Jan and Jan 
1976a,b; Usherwood,  1977; DiAntonio, 2006; 
see recent review Titlow and Cooper, 2018). In 
addition, the P. clarkii NMJs have both 
glutamatergic and GABA-ergic innervation 
profiles, (Bazemore et al., 1956; Van Harreveld 
and Mendelson, 1959; Dudel and Kuffler, 1961a; 
Florey, 1961) which are used for assays of 
pharmacological agents (Van Harreveld 
1959,1980; Shinozaki and Ishida, 1981a,b,c; 
Shinozaki et al., 1982; Bhatt and  Cooper, 2015; 
Lee et al., 2009). Alterations in both quantal 
amplitudes and area of quantal shapes are 
indicative of action on fundamental synaptic 
properties by neurotransmitters. These are readily 
measured at P. clarkii and larval D. melanogaster 
NMJs (Cooper et al., 1995).  
Both preparations produced graded 
evoked responses which are related to the 
synaptic efficacy of multiple quantal fusion 
events and spontaneous single quantal events. 
These are readily obtained with intracellular and 
extracellular recordings on identifiable muscle 
fibers (Dudel and Kuffler, 1961b; Pawlu et al., 
2004). Thus, these two model synaptic 
preparations were utilized in this study to further 
assess the effects of HYC on synaptic 
transmission.  Any changes in the amplitude of 
evoked excitatory postsynaptic potentials 
(EPSPs) were investigated for HYC effects on 
glutamate receptors at these two model NMJs. To 
investigate any potential presynaptic 
contributions by HYC and the influence of Ca2+ 
on facilitation and depression, varied 
concentrations of Ca2+ in bathing saline were 
used with exposure to HYC. This study was 
designed and executed with the intention of 
progressing understanding of the mechanistic 
actions of HCY on glutamatergic non-NMDA 
receptors. Such information could be utilized to 
provide improved treatment of HHcy pathologies 
and symptoms, including difficulty forming new 
memories, therefore providing a deeper 
understanding of neuropathologies such as 
Alzheimer’s disease and Parkinson’s disease.  
Material and Methods 
Animals  
Both P. clarkii and D. melanogaster 
glutamatergic were utilized. These synapses are 
commonly used to assay pharmacological agents. 
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The graded EPSPs of the P. clarkii opener NMJ 
are easier to measure reliably when the responses 
are facilitated to obtain an amplitude of the 
synaptic responses above the noise level. Thus, 
ten stimuli delivered at 40 Hz produces a 
reasonable EPSP response for the 10th response to 
measures (Figure 1A). The changes over time 
were measured by change in response of the 10th 
EPSP during exposure to HCY (100 µM). A 
representative preparation in which the EPSPs 
were monitored over time is illustrated (Figure 
1B).  
 
Experiments were performed using P. 
clarkii, measuring six– eight cm in body length 
(obtained from Atchafalaya Biological Supply 
Co., Raceland, LA, USA). Six P. clarkia were 
individually stored in an aquatic facility at room 
temperature (20-21°C) and were fed commercial 
fish food pellets (Aquadine) for at least two 
weeks prior to experimentation.  
 
The general maintenance in culturing 
Drosophila as well as staging of instars and the 
developmental cycle are described in Campos-
Ortega and Hartenstein (1985). All animals were 
maintained in vials partially filled with a 
cornmeal-agar-dextrose-yeast medium as 
described in Cooper and Cooper (2004). Wild 
type Canton S (CS) flies were used for analyses 
via the semi-intact method. This method involves 
cutting along the dorsal midline to expose the 
body wall muscles and the nervous system 
(Stewart et al., 1994).  This Drosophila strain has 
been isogenic in the lab for several years and was 
originally obtained from Bloomington Fly Stock. 
To obtain 3rd instar staged larvae, the larvae were 
held at 25 °C in a 12 h light/dark incubator before 
being selected.  
 
Electrophysiological recordings of NMJs in P. 
clarkii 
In brief, the excitatory neuron is isolated 
from the inhibitor neuron and stimulated in the 
meropodite segment. The most distal fibers of the 
opener were always used for recording synaptic  
responses (Figure 2A). The stimulation paradigm 
consisted of providing a train (series of electrical 
pulses) of 20 pulses at 40 Hz with ten seconds 
between trains. An average of 20 trains in each of 
the conditions was used for measures of EPSPs. 
Preparations were not stimulated during control 
periods to obtain spontaneous quantal events.  
 
Dissected preparations were maintained 
in saline; a modified van Harreveld’s solution (in 
mM: 205 NaCl, 5.3 KCl, 13.5 CaCl2·2H2O, 2.45 
MgCl2·6H2O, and 5 HEPES adjusted to pH 7.4). 
All the experiments were performed at room 
temperature. Intracellular recordings were made 
with a sharp glass electrode filled with 3.0 M 
KCl, and both recorded and analyzed via Scope 
and LabChart software (AD Instruments). The 
Figure 1: The effects of homocysteine (HCY) on the 
glutamatergic synaptic responses at the P. clarkii 
neuromuscular junction. (A) The amplitude of tenth EPSP 
produced by 40Hz stimulation is used as an index of 
synaptic transmission. (B) A representative response from 
a preparation in which the tenth EPSP is monitored before 
and during the exposure to HCY (100 µM). The box 
outlines indicate the time period used to obtain a mean 
amplitude of the EPSPs to be used to calculate percent 
differences in amplitude due to exposure to HCY. (C) The 
mean amplitude of the EPSPs before and during exposure 
to HCY for each of the six preparations. (D) The mean 
percent difference in the six preparations obtained before 
and during exposure to HCY. No significant effect in EPSP 
amplitude was noted due to exposure to HCY. 
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amplitudes of the EPSPs spontaneous quantal 
events (mEPSPs) elicited by the motor nerve 
were recorded. Intracellular responses were 
recorded with a 1 x LU head stage and an 
Axoclamp 2A amplifier (Molecular Devices, 
Sunnyvale, CA, USA). HCY was made fresh in 
the physiological saline the day of 
experimentation. All chemicals were obtained 
from SIGMA-Aldrich (St. Louis, MO, USA). 
 
Electrophysiological recordings of NMJs in 
larval Drosophila 
The synaptic responses at the larval D. 
melanogaster NMJs were recorded by standard 
procedures (Lee et al., 2009) with stimulation at 
0.5 Hz (Figure 2B). The modified HL3 saline was 
used for physiological measures (Stewart et al., 
1994) at a pH of 7.1 (de Castro et al., 2014). 
Saline solution (in mM): 1.0 CaCl2·2H2O, 70 
NaCl, 20 MgCl2, 5 KCl, 10NaHCO3, 5 trehalose, 
115 sucrose, 25 5N,N-bis(2-hydoxyethyl)-2-
aminoethanesulfonic acid (BES)) was utilized. 
HCY (100 µM) was made fresh in the 
physiological saline the day of experimentation. 
All the experiments were performed at room 
temperatures (20–21◦C). EPSPs were measured 
by intracellular recordings with a sharp glass 
electrode (3 M KCl) and AxoClamp-2 B 
amplifier (Molecular Devices, Sunnyvale, CA, 
USA). Stimulations were made with a Grass S88 
dual stimulator (Natus Neurology Incorporated, 
Middleton, WI, USA). Preparations were used 
immediately after dissection. Electrical signals 
were recorded online to a computer via a 
PowerLab/4s interface (AD Instruments, 
Colorado Springs, CO, USA). Seven larval D. 
melanogaster preparations were dissected as 
previously described (Li et al., 2001) for early 
third instars.  Each D. melanogaster preparation 
was used to measure EPSPs in the same muscle 
fiber in both saline and in the presence of HCY, 
therefore giving a baseline control for that 
individual preparation. All chemicals were 
obtained from Sigma-Aldrich (St. Louis, MO). 
All measures were made in muscle six of 
segments three or four. 
 
Statistical analysis 
 
All data are expressed as an average 
value along with the standard error of the mean 
(i.e., + SEM). The rank sum pairwise test or a sign 
test was used to compare the differences in 
responses before and after exchanging a solution 
with saline containing the compounds. This 
analysis was performed with Sigma Stat 
software. P of < 0.05 is considered to be 
statistically significant. 
 
Results 
 To examine for an effect due to exposure 
to HCY, the mean amplitude of the tenth EPSP 
from an average of at least 20 responses was 
compared during saline exposure and during 
HCY exposure (Figure 1C). The percent 
difference in each of the six preparations before 
and during exposure to HCY revealed no 
Figure 2: The P. clarkii and larval D. melanogaster 
preparations. (A) The most distal muscle fibers of the P. 
clarkii opener muscle in the first walking leg provides a 
common target among preparations. The opener muscle 
does show regional differences in amplitudes of EPSPs. 
The excitatory motor neuron is selectively stimulated in 
a more proximal segment of the leg while monitoring the 
EPSPs produced. (B) The body wall muscle named m6 of 
the third or fourth segments in the dissected early third 
instar larvae are used to measure the evoked EPSP. Body 
wall muscle m6 and m7 are shown in each segment. The 
segmental nerve to the segment of interest is stimulated 
with a suction electrode which contains the segmental 
nerve. 
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significant trend (P > 0.05, sign test) to an effect 
on the EPSP amplitude at the P. clarkii NMJ 
(Figure 2D). The mean percent difference was 
1.33 (4.8+/- SEM). 
 The graded evoked response at the larval 
D. melanogaster NMJ on muscle 6 produced a 
large enough EPSP that facilitation of the 
synaptic response was not necessary as for the P. 
clarkii opener NMJs (Figure 3A). The amplitude 
of the EPSPs over time for a representative 
preparation illustrated that no large changes 
occurred upon exposure to HCY (100 µM) 
(Figure 3B). The blocked regions in the trace 
indicated the region of time used to calculate the 
mean EPSP amplitude used for quantification in 
determining a percent change due to HCY 
exposure. The mean amplitudes for each of the 
seven preparations before and during exposure to 
HCY is shown (Figure 3C). The percent 
difference in the seven preparations before and 
during exposure to HCY revealed no significant 
trend (P > 0.05, sign test) in an effect on the EPSP 
amplitude at the larval D. melanogaster NMJ 
(Figure 3D). The mean percent difference was 
0.13 (4.2+/- SEM). 
 
Discussion 
In this study, we demonstrated that HCY 
at 100 µM did not have any effect on synaptic 
transmission at the NMJs of the P. clarkii and 
larval D. melanogaster. This differed from our 
hypothesis that application of HCY to 
glutamatergic synapses in D. melanogaster and 
P. clarkii would be inhibited by a high HCY 
concentration via competition for the release of 
glutamate at the NMJ. Despite these 
glutamatergic synaptic preparations having non-
NMDA receptor subtypes postsynaptically, and 
that it was established that HCY could influence 
non-NMDA receptors in mammalian CNS 
preparations (Yuzaki and Connor, 1999), no 
detectable differences in the amplitude of the 
evoked EPSPs could be ascertained.  It is likely 
the extracellular domain of the quisqualate 
subtype glutamate receptors of the P. clarkii and 
larval D. melanogaster NMJs is significantly 
divergent such that they are unreceptive to HCY 
(Lee et al., 2009). It is known that the GluN2A 
subunit of the NMDA receptors is key to HCY 
having an effect (Sibarov et al., 2016). 
Potentially, the extracellular domains of the 
different receptor make up could be compared 
with bioinformatics to estimate the 3-dimensional 
configuration required for HCY sensitivity. It is 
known that exposure to the P. clarkii or larval D. 
melanogaster NMJs to 100 µM of glutamate that 
depolarization will occur followed by 
desensitization and a reduce amplitude in the 
evoked EPSP (Lee et al., 2009; Titlow and 
Cooper, 2018). So, if HCY was to act as an 
Figure 3: The effects of homocysteine (HCY) on the 
glutamatergic synaptic responses at the larval D. 
melanogaster neuromuscular junction. (A) The 
amplitude of the EPSP used as an index of synaptic 
transmission. (B) A representative response from a 
preparation in which the EPSP is monitored before and 
during the exposure to HCY (100 µM). The box outlines 
indicate the time period used to obtain a mean amplitude 
of the EPSPs to be used to calculate a % differences in 
amplitudes due to exposure to HCY. (C) The mean 
amplitude of the EPSPs before after during exposure to 
HCY for each of the seven preparations. (D) The mean 
percent difference in the seven preparations with before 
and during exposure of HCY. No significant effect is 
noted due to exposure of HCY. 
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agonist we would have expect some alteration in 
response at a similar concentration. 
The lack of an acute or longer term effect 
by HCY at such high concentration is most likely 
explained that the glutamate receptors on both 
preparations is not sensitive to HCY. If one was 
interested in knowing the precise structural 
elements required for HCY to have an action, 
various glutamate receptors subunits, with 
sequence alterations, could be expressed in a cell 
line or frog oocytes and examined for responses 
to HCY.  
In mammals, HCY acts on the CNS to 
alter various functions such as sympathetic 
activity, and may even be related to inducing 
cardiovascular pathologies (Zhong et al., 2017). 
The physiological profiling of the glutamatergic 
receptors within the CNS or the equivalent 
ventral nerve cord of larval D. melanogaster and 
P. clarkii has not been performed. Perhaps there 
may be actions of HCY on the central 
glutamatergic synapses in these invertebrate 
preparations as for mammals. Further studies will 
need to be conducted to determine if these 
invertebrate models have similar central 
responses to HCY as mammals.  
 Since D. melanogaster are known 
synthesize HCY, (Caggese et al., 1997) it is 
probable other insects and crustaceans synthesize 
it as well due to physiological and biochemical 
similarities between species of arthropods. The 
crustaceans are similar to insects in many ways 
related to neural function. At this point, 
investigations have yet to be conducted to 
determine if HCY is present in the CNS of 
crustaceans.  However, one of the proposed long-
range treatments by health food supplement aids 
for HHcy in humans is to have a diet high in 
marine crustaceans (Tou et al., 2007; Naushad et 
al., 2017) as it has been shown that a diet of Arctic 
krill for rodents reduces HCY levels in the blood 
(Bjørndal et al., 2015). We could not find any 
scientific studies using humans to directly show 
that a diet of marine crustaceans was beneficial 
for human treatment of HHcy pathologies.  The 
mechanisms in the rodents for reducing HCY is 
most likely due to the n-3 polyunsaturated fatty 
acids in the muscle and vitamins B12, B6, and 
folate in krill (Bjørndal et al., 2015; 
Krajcovicová-Kudlácková and Blazícek, 2002).   
 Future studies would be of interest to 
determine any potential central effects of HCY in 
invertebrates, particularly D. melanogaster, as 
genetic models of degradation of HCY could 
potentially be utilized to look at long term 
consequences on neural development with raised 
HCY as it relates to consequences in mammals. 
As a comparative investigation, it would be of 
interest to know if crustaceans also produce HCY 
in the CNS. This could be determined through 
analysis of HCY levels in varied areas of interest 
within the CNS, such as the hippocampus and 
blood-brain barrier both at baseline neural 
stimulation and in differing states of stimulation. 
Also of interest would be to determine if an 
altered diet, such as with vitamin B complexes, 
would lower HCY in the CNS of D. 
melanogaster, thus furthering implicating a 
relationship in diet, HCY levels, and possible 
resultant neuroprotective or neurodegenerative 
responses. The understandings that would be 
provided by these further elaborations of this 
experiment could translate to development of 
treatments of aforementioned diseases such as 
Parkinson’s disease and ALS at a much later 
point.  
 The results of this experiment lead to 
several possible implications regarding the 
clinical relevance of using P. clarkii and D. 
melanogaster as models for HHcy and diseases 
with similar pathologies. However, utility of 
these preps remains useful for establishing a basic 
understanding of HCY action at glutamatergic 
receptors, but subsequent experiments attempting 
to draw conclusions regarding clinical 
application would require a model with a subtype 
of glutamatergic receptors that is more similar to 
those found in mammals.
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Endnotes 
Many of the authors were students in a 
neurophysiology lab based class who addressed 
authentic scientific based questions in regard to 
the topic of examining pharmacological agents 
known in other models to block stretch activated 
ion channels. This course project is part of a trend 
in teaching science to undergraduates (Linn et al., 
2015). Course-based undergraduate research 
experiences (CUREs) are an approach being 
adopted by science educators in high schools and 
colleges (Bakshi et al., 2016). Our hope is to 
present a new acronym for authentic course-
based undergraduate research experience 
(ACURE).  
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